Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,117.85
    +38.99 (+0.48%)
     
  • Bitcoin USD

    63,865.13
    +935.90 (+1.49%)
     
  • CMC Crypto 200

    1,385.18
    -11.36 (-0.81%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • Dow

    38,085.80
    -375.12 (-0.98%)
     
  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     
  • Gold

    2,359.80
    +17.30 (+0.74%)
     
  • Crude Oil

    84.26
    +0.69 (+0.83%)
     
  • 10-Yr Bond

    4.6670
    -0.0390 (-0.83%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Here's Why Amyris Stock Rose as Much as 12.2% Today

Here's Why Amyris Stock Rose as Much as 12.2% Today

Shares of Amyris (NASDAQ: AMRS) gained over 12% today after the company announced it had signed a binding term sheet with the Infectious Disease Research Institute (IDRI) to collaborate on a SARS-CoV-2 vaccine candidate. Specifically, IDRI will develop a vaccine candidate based on its RNA vaccine platform, while Amyris will supply squalene for use in the vaccine adjuvant.